Note: Descriptions are shown in the official language in which they were submitted.
WO 2021/168306
PCT/US2021/018856
METHODS OF PREPARING OLIGONUCLEOTIDE COMPOSITIONS USING
ULTRAFILTRATION / DIAFILTRATION
CROSS REFERENCE TO RELATED APPLICATION
This application claims the benefit of the filing date, under 35 U.S.C.
119(e), of U.S.
Provisional application No. 62/979,687, filed on February 21, 2020, the entire
contents of
which are incorporated herein by reference.
FIELD OF THE DISCLOSURE
This application relates to biopharmaceutical technology in general and more
specifically to methods for preparing high-purity oligonucleotide compositions
using
filtration techniques capable of controlling the content of salts in the
oligonucleotide
compositions. Methods of this disclosure successfully link the use of
ultrafiltration /
diafiltration (UF/DF) with lyophilization, in a manner that avoids the need to
perform
additional processing steps that are generally used in the production of
lyophilized (solid)
active pharmaceutical ingredients (APIs).
BACKGROUND
Oligonucleotides are short DNA or RNA oligomers that can be chemically
synthesized for research and medical purposes. Oligonucleotides are typically
prepared by a
stepwise addition of nucleotide residues to produce a specific sequence.
Following
completion of the synthesis of the oligonucleotide in the desired sequence,
the target
oligonucleotide is typically obtained as a mixture along with failed sequences
and other
process and product related impurities.
Preparation of oligonucleotides for therapeutic use, such as commercial
oligonucleotides approved for use by the FDA, is further complicated by
stringent
commercial specifications and drug product validation requirements. Suitable
purification
and formulation techniques for therapeutic oligonucleotides must take into
account the
chemical composition and stability of the product, as well as the mode of
administration.
Therapeutic oligonucleotides are typically prepared using either an aqueous-
based
platform process or a lyophilized API platform process, depending on the form
of the drug
product required. A lyophilized (solid) drug product is potentially preferable
to a liquid drug
product for some products based on stability profiles, ease of storage, and
ease of processing.
1
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
Spinraza (nusinersen) is an antisense oligonucleotide (ASO) drug used for
treating
spinal muscular atrophy (SMA), a rare neuromuscular disorder. Commercial
Spinraza' drug
product is a lyophilized API derived from a solvent-intensive process. There
is a need to
integrate an aqueous based platform process, which ends in a liquid drug
substance produced
via ultrafiltration/diafiltration (UF/DF), with a lyophilized API that has
specified salt (e.g.,
sodium and acetate) content. This approach would minimize drug product
validation and
meet existing commercial specifications without the need to add any non-
platform liquid
volume reduction steps and/or equipment.
SUMMARY OF THE DISCLOSURE
This disclosure describes methods of using ultrafiltration / diafiltration
(UF/DF) to
concentrate and buffer exchange oligonucleotides, in order to obtain aqueous
oligonucleotide
solutions that are suitable for lyophilization without additional
(intervening) processing steps.
FIG. 1 illustrates how methods of this disclosure are capable of integrating
an aqueous-based
platform process using UF/DF with a lyophilized API platform process, in a
manner that
eliminates the need to perform the solvent-based precipitation that generally
precedes the
lyophilization step.
In particular, the methods disclosed herein are capable of controlling pre-
and post-
lyophilization sodium contents as well as post-lyophilization acetate content
in the
oligonucleotide API to meet pre-determined sodium and acetate specifications.
This is
achieved by controlling the components (e.g., salts) in the UF/DF aqueous
buffer solution
The methods described herein are also capable of controlling the membrane
permeate flux
and the retentate concentration of the oligonucleotide while performing the
UF/DF step
within manufacturer recommended conditions of transmembrane pressure (TMP)
One aspect of the present disclosure relates to a method for preparing a
composition
comprising an oligonucleotide, wherein the method comprises subjecting an
aqueous solution
of the oligonucleotide to ultrafiltration / diafiltration (UF/DF) to form a
retentate comprising
the oligonucleotide, and wherein the ultrafiltration/ diafiltration (UF/DF) is
carried out using
an aqueous buffer solution comprising one or more salts.
Another aspect of the present disclosure relates to compositions comprising an
oligonucleotide, wherein the compositions are obtained by one of the methods
described
herein.
In some embodiments, the composition is in the form of an aqueous solution
comprising the oligonucleotide.
2
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
In some embodiments, the composition is in the form of a lyophilized
composition
comprising the oligonucleotide.
Additional objects, advantages and other features of the present disclosure
will be set
forth in part in the description that follows and in part will become apparent
to those having
ordinary skill in the art upon examination of the following or may be learned
from the
practice of the present disclosure. The advantages of the present disclosure
may be realized
and obtained as particularly pointed out in the appended claims. As will be
realized, the
present disclosure is capable of other and different embodiments, and its
several details are
capable of modifications in various obvious respects, all without departing
from the present
disclosure. In this regard, the description herein is to be understood as
illustrative in nature,
and not as restrictive.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 depicts an exemplary integration of a solvent intensive process with an
aqueous based process of the present disclosure.
FIG. 2 is a graph illustrating permeate flux drops during buffer exchange when
UF/DF is performed at different ammonium acetate concentrations.
FIG. 3 is a graph illustrating the DF buffer effect on second steady state
permeate
flux as DF buffer conductivity is increased.
FIG. 4 is a graph illustrating maximum ASO concentration in a retentate versus
total
concentration of acetate salts in the UF/DF buffer.
FIG. 5 is a graph illustrating post lyophilization (post-lyo) trends for
sodium and
ammonium content.
FIG. 6 is a graph illustrating the sodium (Na) content in the post UF/DF
retentate
versus the percentage (%) of sodium acetate (Na0Ac) in UF buffers containing
different
amount ammonium acetate (NH40Ac).
FIG. 7 is a picture of an exemplary lyophilizer chamber with LyoGuard trays.
FIG. 8 is a picture of an exemplary lyophilized ASO material in the tray and
bag.
3
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
FIG. 9 is a graph illustrating how permeate flux drops as the concentration of
the
oligonucleotide in the retentate increases when UF/DF is carried out in water.
FIG. 10 is a graph illustrating the percentage (%) by mass of acetate (0Ac)
remaining
in a solid API versus the total concentration of acetate (0Ac) in the UF
buffer.
FIG. 11 illustrates a comparison between an exemplary aqueous-based platform
process and an exemplary lyophilized API platform process including a ethanol
precipitation
step.
FIG. 12 illustrates how sodium (Nat) ions and ammonium (NH4) ions may occupy
different counterion positions along a negatively charged phosphorothioate
oligonucleotide
backbone.
DETAILED DESCRIPTION
Disclosed herein are methods that integrate the use of ultrafiltration /
diafiltration
(UF/DF) into a lyophilized API platform process that is traditionally used to
prepare solid
form of oligonucleotide active pharmaceutical ingredients (APIs). Embodiments
of this
disclosure include methods for preparing oligonucleotides for therapeutic use,
such as
anti sense oligonucleotide Spinraza (nusinersen).
An aqueous-based platform process generally involves one or two chromatography
separation steps, a deprotection step, and ending in an
ultrafiltration/diafiltration (UF/DF)
step that concentrates the oligonucleotide of interest and executes buffer
exchange into a
liquid formulation suitable for intrathecal (IT) administration. This platform
delivers a liquid
drug substance from the UF/DF operation to the parenteral fill facility for
final dilution,
filtration and filling. In contrast, a lyophilized API platform process often
utilizes a solvent
based purification process. FIG 11 illustrates the differences between an
aqueous-based
platform process used to prepare a ready-to-fill liquid form of Spinraza
(nusinersen) versus
a lyophilized API platform process used to prepare a lyophilized (solid) form
of this product.
As shown in FIG 11, the aqueous-based platform process of Spinraza comprises
an ion
exchange chromatography step followed by an ultrafiltration / diafiltration
(UF/DF) step to
obtain a ready-to-fill liquid form of Spinraza (nusinersen). By contrast, the
lyophilized API
platform process includes an ethanol precipitation step followed by
lyophilization and
compounding to obtain a lyophilized (solid) form of drug product.
4
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
It would be advantageous to modify the lyophilized API platform process,
currently
used to prepare commercial Spinraza (nusinersen), by replacing the ethanol
precipitation
step with the UF/DF step used in the aqueous-based platform process. First,
for both
environmental and regulatory reasons, it would be advantageous to eliminate
the use of
organic solvents in the final preparation of this commercial product. Second,
because UF/DF
can typically be used to precisely control the content of salts in the
processed product, greater
control of salt content could be obtained by using UF/DF instead of solvent
precipitation.
However, as explained below, due to the practical limitations of UF/DF and
large-scale
lyophilization, it has not previously been possible to successfully integrate
these processes
into the commercial-scale preparation of Spinraze without including additional
steps.
The difficulty of integrating UF/DF into a large-scale lyophilization occurs
largely
due to salt content and/or oligonucleotide content in the aqueous retentate
that results from
UF/DF Whereas Spinraza' (nusinersen) is required to have a relatively low
content of
salts
____________________________________________________________________________
including a sodium content of around 5% by weight in the lyophilized product
attempting to perform UF/DF with an aqueous solution having such a low salt
content (and
low conductivity) leads to low permeate flux through the membrane. This low
permeate flux
occurs, in part, due to undesirable "caking" that forms on the retentate face
of the UF/DF
membrane. The low permeate flux leads to both a reduction in the production
rate of the
desired oligonucleotide and in the concentration of the oligonucleotide in the
retentate. To
successfully operate the UF/DF and reach ASO concentrations ideal for
lyophilization, a
minimum amount of conductivity is needed in the UF/DF buffer. On the other
hand, if the
salt content of the UF/DF buffer is increased to a level necessary to permit a
suitably high
permeate flux rate (resulting in a suitably high concentration of the
oligonucleotide in the
retentate), then the resulting retentate contains too much salt, which will
require additional
step(s) to remove unwanted salts.
The methods of the present disclosure successfully overcome these difficulties
by
controlling salt concentration and salt content in the buffer solution. The
methods integrate
an aqueous purification process with a lyophilization step to create a solid
API with pre-
determined specifications for sodium and acetate, without adding additional
steps and/or
equipment. Success of the UF/DF process is determined both by operability of
the UF/DF
operation (flux and concentration), and the composition of the solid API after
the post-UF/DF
product has been processed by lyophilization. The UF/DF process was developed
in which a
purification process intermediate, which contains not only the target
oligonucleotide but
various molecular species involved in the purification process, is
concentrated and processed
5
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
by UF/DF such that a target sodium content is achieved post-lyophilization,
and an acetate
specification is met post-lyophilization. The UF/DF process of the present
disclosure
achieves control of the total sodium content by controlling the average number
of sodium
cations occupying counterion positions along the negatively charged
phosphorothioate or
phosphorodiester oligonucleotide backbone. The new methods also facilitate
efficient
operation of the UF/DF process by meeting minimum membrane permeate flux and
maximum retentate concentration required for large scale manufacturing
processes.
Unless otherwise defined, all technical and scientific terms used herein have
the same
meaning as commonly understood by persons of ordinary skill in the relevant
art. In case of
conflict, the present specification, including definitions, will control.
Unless stated otherwise, all percentages, parts, ratios, etc., are by weight.
When an amount, concentration, or other value or parameter is given as a
range, or a
list of upper and lower values, this is to be understood as specifically
disclosing all ranges
formed from any pair of any upper and lower range limits, regardless of
whether ranges are
separately disclosed. Where a range of numerical values is recited herein,
unless otherwise
stated, the range is intended to include the endpoints thereof, and all
integers and fractions
within the range. It is not intended that the scope of the present disclosure
is to be limited to
the specific values recited when defining a range.
The use of "a- or "an" to describe the various elements and components herein
is
merely for convenience and to give a general sense of the disclosure. This
description should
be read to include one or at least one and the singular also includes the
plural unless it is clear
that it is otherwise intended.
When a specified amount or value is used, it should be understood to encompass
slight deviation from the specified amount or value, which one skilled in the
art would
understand as equivalent to or substantially the same as the specified amount
or value. In
some embodiments, a specified amount or value encompass 10% of the specified
amount or
value. In some embodiments, a specified amount or value encompass 5% of the
specified
amount or value.
One aspect of the present disclosure relates to methods for preparing
compositions
containing oligonucleotides, such as Spinraza (nusinersen). The methods
comprise
subjecting an aqueous solution of the oligonucleotide to ultrafiltration /
diafiltration (UF/DF)
to form a retentate comprising the oligonucleotide, wherein the
ultrafiltration / diafiltration
(UF/DF) is carried out using an aqueous buffer solution comprising one or more
salts.
6
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
In some embodiments, the one or more salts in the aqueous buffer solution may
be
formulated in a manner that ultimately controls the composition of the
retentate. For example,
in some embodiments the aqueous buffer solution may be formulated so as to
control the
sodium content of the retentate produced by the UF/DF¨thereby indirectly
controlling the
sodium content of the lyophilized product. Such control is enabled by the
presence of a
plurality of salts in the aqueous buffer solution, including a sodium salt and
a competitive salt
having a different cation than sodium. Competitive salts include, for example,
salts having
different cations, such as ammonium, dimethylammonium, trimethylammonium,
potassium,
lithium, rubidium, copper, silver, or other suitable monovalent cations. The
competitive salt
may be a volatile salt, a non-volatile salt, or a combination thereof.
In some embodiments, the use of at least one competitive salt enables methods
of the
present disclosure to control the average number of sodium cations occupying
the counterion
positions of the oligonucleotide backbone FIG 12 illustrates how sodium (Nat)
ions and
ammonium (NH4) ions may occupy different counterion positions along a
negatively-
charged phosphorothioate or phosphorodiester oligonucleotide backbone. Thus,
in some
embodiments, the present disclosure provides methods for controlling sodium
content in the
oligonucleotide retentate produced by the UF/DF by the introduction of one of
more
competitive salts in the aqueous buffer solution. In other words, the methods
of present
disclosure comprises subjecting an aqueous solution of the oligonucleotide to
ultrafiltration /
diafiltration (UF/DF) to form a retentate comprising the oligonucleotide,
wherein the
ultrafiltration/ diafiltration (UF/DF) is carried out using an aqueous buffer
solution
comprising a sodium salt and a competitive salt. In some embodiments, the
competitive salt
is a potassium salt. In other embodiments, the competitive salt is an ammonium
salt.
After buffer exchange of an aqueous solution containing both sodium cations
and
competitive cations occurs, the sodium and competitive cations reach an
equilibrium on the
counterion positions on the oligonucleotide, resulting in an oligonucleotide
in solution that is
not completely sodiated, i.e., oligonucleotide counterion positions are not
completely
occupied by sodium cations. See FIG. 12. This equilibrium ratio can be
expressed as follows:
(moles of competitive cation'\
moles of SOdiarn
k,
moles of oliganucleotide
and is controlled by the molar ratio of the competitive cation(s) to the
sodium cation in the
aqueous buffer solution used during the UF/DF process.
7
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
The properties of the competitive salt can affect not only the composition of
the
retentate following the UF/DF process, but can also affect the final
composition of the solid
product following lyophilization. For example, when the competitive salt is a
volatile salt, it
is possible to lower the total salt content of the lyophilized product
(relative to the total salt
content of the retentate) without affecting the sodium content.
In some embodiments, the one or more salts contained in the aqueous buffer
solution
may include at least one volatile salt. The UF/DF processes of the present
disclosure that
utilize volatile salts can achieve maximum ASO concentration in the retentate
solutions with
desired sodium content. The use of volatile competitive salts to lower the
total salt content in
the lyophilized product (relative to the total salt content of the retentate)
is possible due to the
acid-base properties of volatile salts. In a volatile competitive salt, the
volatile competitive
cation of the salt exists in equilibrium with a corresponding volatile
conjugate base. The
volatility of the competitive cation species (in its neutral form with the
corresponding
conjugate base) allows for its removal by sublimation during lyophilization.
Ammonium acetate (NH40Ac) is an example of a volatile competitive salt used in
some embodiments of the present disclosure. As shown below, the ammonium
cation (NH4)
exists in equilibrium with ammonia (NH3), while the acetate anion (Ac0-)
exists in
equilibrium with acetic acid (AcOH).
NH4+ = Ac0- NH3 + AcOH
In the equilibrium shown above, the protonated ammonium cation serves as a
proton
source for converting the acetate anion into acetic acid, which is volatile
and can be removed
by lyophilization. The proton transfer from the ammonium to the acetate
renders both species
neutral and volatile, facilitating the removal of both species during
lyophilization.
Other exemplary volatile competitive salts include, for example, ammonium
salts of
formic acid, propionic acid, butyric acid, lactic acid and carbonic acid.
By use of a volatile competitive salt, such as the ammonium acetate
illustrated above,
a subsequent lyophilization of the post-UF/DF retentate can be performed in a
manner that
removes significant quantities of the volatile competitive salt¨while still
maintaining the
sodium content of the retentate. Thus, it is possible through the use of a
volatile competitive
salt to produce a lyophilized oligonucleotide composition having a sodium
content that is
controlled based on the composition of the aqueous buffer solution, while also
having a total
salt content that is significantly less than the total salt content of the
post-UF/DF retentate.
By this feature, methods of the present disclosure can produce solid,
oligonucleotide APIs
8
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
having a pre-determined sodium content while removing the competitive salt to
trace
quantities.
In some embodiments, the competitive salt may be a non-volatile salt that is
not
removed by lyophilization. For example, the aqueous buffer solution may
include a sodium
salt, such as the sodium acetate, sodium chloride, sodium bromide or sodium
iodide, and a
non-volatile competitive salt, such as potassium acetate, potassium chloride,
potassium
bromide or potassium iodide. Other non-volatile competitive salts include, for
example,
potassium salts, lithium salts (e.g., lithium acetate, lithium chloride,
lithium bromide or
lithium iodide), rubidium salts (e.g., rubidium acetate, rubidium chloride,
rubidium bromide,
or rubidium iodide), copper salts (e.g., copper acetate, copper chloride,
copper bromide or
copper iodide) and silver salts (e.g. silver acetate, silver chloride, silver
bromide or silver
iodide).
In the methods of the present disclosure, the composition of the aqueous
buffer
solution can be controlled to target a wide range of sodium content in the
post-UF/DF
retentate and in the post-lyophilization product¨from essentially zero sodium
content to
sodium contents much greater than the equivalent of a fully sodiated ASO.
In some embodiments, the aqueous buffer solution comprises at least one salt
selected
from sodium acetate, ammonium acetate and potassium acetate. In some
embodiments, the
aqueous buffer solution comprises sodium acetate and ammonium acetate. In some
embodiments, the aqueous buffer solution comprises sodium acetate and
potassium acetate.
In other embodiments, the aqueous buffer solution comprises sodium acetate,
ammonium
acetate and potassium acetate.
In some embodiments, the sodium content (e.g. sodium concentration) in the
oligonucleotide-containing retentate is controlled by adjusting the proportion
of at least one
sodium salt relative to the total concentration of salts in the aqueous buffer
solution. In other
embodiments, the proportion of sodium cations occupying counterion positions
of the
oligonucleotide in the retentate is controlled by adjusting the proportion of
the at least one
sodium salt relative to the total concentration of salts in the aqueous buffer
solution.
In some embodiments, the molar ratio of the sodium salt to the competitive
salt
contained in the aqueous buffer solution ranges from 1:100 to 100:1, or from
1:20 to 20:1, or
from 1:10 to 10:1, or from 1:1 to 19:1, or from 5:1 to 19:1, or from 12:1 to
15:1, or from 5:1
to 10:1, or from 5:1 to 6:1, or from 5:1 to 6:1.8.
In some embodiments, the aqueous buffer solution comprises sodium acetate and
ammonium acetate and the molar ratio of sodium acetate to ammonium acetate in
the aqueous
9
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
buffer solution ranges from 1:100 to 100:1, or from 1:20 to 20:1, or from 1:10
to 10:1, or
from 1:1 to 19:1, or from 5:1 to 19:1, or from 12:1 to 15:1, or from 5.1 to
10:1, or from 5:1 to
6:1, or from 5:1 to 6:1.8. In some embodiments, the molar ratio of sodium
acetate to
ammonium acetate is 17:3. In some embodiments, the aqueous buffer solution
comprises 34
mM of sodium acetate and 6 mM of ammonium acetate.
In some embodiments, the aqueous buffer solution comprises sodium acetate and
potassium acetate and the molar ratio of sodium acetate to potassium acetate
in the aqueous
buffer solution ranges from 1:100 to 100:1, or from 1:20 to 20:1, or from 1:10
to 10:1, or
from 1:1 to 19:1, or from 5:1 to 19:1, or from 12:1 to 15:1, or from 5:1 to
10:1, or from 5:1 to
6:1, or from 5:1 to 6:1.8. In some embodiments, the molar ratio of sodium
acetate to
potassium acetate is 17:3. In some embodiments, the aqueous buffer solution
comprises 34
mM of sodium acetate and 6 mM of potassium acetate.
In some embodiments, the pH of the aqueous buffer solution ranges from 4.0 to
10_U,
or from 4.5 to 9.5, or from 5.0 to 9.0, or from 5.0 to 8.5, or from 5.0 to
8.0, or from 5.5 to 9.0,
or from 5.5 to 8.5, or from 5.5 to 8.0, or from 5.5 to 7.5, or from 6.0 to
9.0, or from 6.0 to 8.5,
or from 6.0 to 7.5, or from 6.0 to 7.0, or from 6.5 to 9.0, or from 6.5 to
8.5, or from 6.5 to 8.0,
or from 6.5 to 7.5, or from 6.9 to 7.5.
In some embodiments, the aqueous buffer solution does not contain any sodium
salt,
such that the post-UF/DF retentate contains no sodium. In other embodiments,
the aqueous
buffer solution does not contain any competitive salt.
In some embodiments, methods of the present disclosure may include a step of
lyophilizing the UF/DF retentate to produce lyophilized compositions
comprising the target
oligonucleotide. The lyophilization can remove volatile UF/DF buffer
components (e.g.,
volatile competitive salt, such as ammonium acetate salt). The lyophilization
step may be
carried out as a single lyophilization, or may be carried out as a plurality
of lyophilizations
occurring in a single lyophilization apparatus or in multiple lyophilization
apparatuses.
In some embodiments, the proportion of one or more competitive salts contained
in
the lyophilized composition is less than the proportion of the one or more
competitive salts
contained in the post-UF/DF retentate. For example, as explained above, the
volatile
competitive salts, such as ammonium acetate, in the aqueous buffer solution
can be
subsequently removed (in part or in full) during lyophilization.
Methods of the present disclosure may also include a step of adjusting the pH
of the
post-UF/DF retentate prior to performing a lyophilization. In some
embodiments, the pH of
the retentate is adjusted to a pH in the range of from 5.0 to 9.0, or from 5.0
to 8.5, or from 5.0
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
to 8.0, or from 5.5 to 9.0, or from 5.5 to 8.5, or from 5.5 to 8.0, or from
5.5 to 7.5, or from 6.0
to 9.0, or from 6.0 to 8.5, or from 6.0 to 7.5, or from 6.0 to 7.0, or from
6.5 to 9.0, or from 6.5
to 8.5, or from 6.5 to 8.0, or from 6.5 to 7.5. In one embodiment, the pH of
retentate is
adjusted to a pH in the range of 6.9 to 7.5.
The methods of the present disclosure are capable of controlling the
proportion of
sodium contained in lyophilized compositions with great precision. In some
embodiments,
the weight percentage of sodium in the lyophilized composition ranges from 0%
to 100%, or
from 0% to 50%, or from 1% to 25%, or from 1% to 10%, or from 2% to 10%, or
from 1% to
5%, or from 5% to 10%, or from 4.3% to 6.1%, or from 4.8% to 5.4%, or from
4.9% to 5.0%,
relative to the total weight of the lyophilized composition. In some
embodiments, the weight
percentage of sodium in the lyophilized composition is 5.2% + 0.9%. In some
embodiments,
the oligonucleotide is nusinersen and the weight percentage of sodium in the
lyophilized
composition of nusinersen is 5.2% 0.9%.
For the methods of the present disclosure, the concentration of the
oligonucleotide in
the post-UF/DF retentate can be indirectly controlled by adjusting the total
concentration of
salts (and consequently the conductivity) in the aqueous buffer solution.
Although performing
the UF/DF using deionized water would preserve the sodium content of a fully
sodiated ASO,
it is not feasible to carry out UF/DF of oligonucleotides in pure water that
can be directly
lyophilized due to limitations of permeate flux and maximum retentate
concentration. UF/DF
processing of oligonucleotides in water was found to be limited by membrane
surface gelling
or concentration polarization phenomena, leading to reduced membrane permeate
flux and
creating a maximum achievable retentate concentration of only 30-40 g/L.
To successfully operate the UF/DF and reach ASO concentrations ideal for
lyophilization (i.e., at least 50 g/L), it was discovered that a minimum
amount of salt
concentration (and conductivity) is needed in the UF/DF buffer. The effect of
salt
concentration and conductivity on permeate flux is illustrated in FIGs 2 and
3. As shown in
the study of FIG. 2, when a series of UF/DF processes were carried out using
different
concentrations of ammonium acetate, the permeate flux was observed to be
dramatically
reduced when using lower concentrations of the ammonium acetate, and the
permeate flux
was further reduced dramatically as the number of diavolumes of the UF/DF
increased. As
shown in FIG. 3, The total salt concentration is proportional to the membrane
permeate flux
at a given TMP.
Based on this observation, it was discovered that the total salt concentration
in the
aqueous buffer solution can be used to control the permeate flux of the UF/DF
process and
11
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
the concentration of the oligonucleotide in the post-UF/DF retentate. As
illustrated in the
study of FIG. 4, it was discovered that the final retentate ASO concentration
can be increased
by increasing the concentration of acetate salts in the aqueous buffer
solution. Because an
increase in the total salt concentration in the aqueous buffer solution leads
to an increase in
both the permeate flux and the maximum concentration of the oligonucleotide in
the retentate,
methods of the present disclosure can be used to achieve a desired permeate
flux and a
suitably-high retentate concentration to enable large-scale lyophilization
without additional
(i.e., solvent removal) steps.
In some embodiments, the total concentration of the one or more salts in the
aqueous
buffer solution ranges from 1 mM to 500 mM, or from 10 mM to 200 mM, or from
20 mM to
100 mM, or from 30 mM to 60 mM, or from 35 mM to 45 mM. In some embodiments,
the
total concentration of the one or more salts in the aqueous buffer solution is
40 mM.
When acetate salts are used as components of the aqueous buffer solution, it
may be
necessary to remove these salts to trace levels during the lyophilization. As
illustrated in the
study of FIG. 10, the acetate content in the solid API was also found to be
proportional to the
total salt concentration (and therefore to the total acetate concentration) in
the aqueous buffer
solution. Therefore, the total acetate content of the UF/DF buffer can be
controlled to reduce
the acetate in the solid API to trace levels. In some embodiments, the use of
volatile acetate
salts such as ammonium acetate can further reduce the final acetate content
due to the
removal of the volatile acetate salts during the lyophilization.
In some embodiments, the aqueous buffer solution comprises sodium acetate and
ammonium acetate and the total concentration of sodium acetate and ammonium
acetate in
the aqueous buffer solution ranges from 1 mM to 500 mM, or from 10 mM to 200
mM, or
from 20 mM to 100 mM, or from 30 mM to 60 mM, or from 35 mM to 45 mM. In some
embodiments, the total concentration of sodium acetate and ammonium acetate in
the
aqueous buffer solution is 40 mM.
In other embodiments, the aqueous buffer solution comprises sodium acetate and
potassium acetate and the total concentration of sodium acetate and potassium
acetate ranges
from 1 mM to 500 mM, or from 10 mM to 200 mM, or from 20 mM to 100 mM, or from
30
mM to 60 mM, or from 35 mM to 45 mM. In some embodiments, the total
concentration of
sodium acetate and potassium acetate in the aqueous buffer solution is 40 mM.
In some embodiments, the weight percentage of acetate in the lyophilized
composition is less than 5%, or is less than 4%, or is less than 3%, or is
less than 2%, or is
less than 1%, or is less than 0.8%, or is less than 0.5%, or is less than
0.2%, relative to the
12
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
total weight of the lyophilized composition. For example, in some embodiments,
the weight
percentage of acetate in the lyophilized composition ranges from 5% to 0.1%,
or from 5% to
0.5%, or from 5% to 1%, or from 3% to 0.5%, or from 3% to 0.2%, or from 2% to
0.5%, or
from 2% to 1%, or from 1% to 0.5%, or from 1% to 0.1%, or from 0.8% to 0.1%,
or from
0.5% to 0.1%, or from 0.2% to 0.01%, relative to the total weight of the
lyophilized
composition.
The composition and properties of the aqueous buffer solution can be
controlled in
order to maximize the permeate flux of the UF/DF process, see FIGs. 2 and 3.
Thus, the
present disclosure provides methods of controlling the permeate flux of UF/DF
process by
adjusting the total concentration of one or more salts in the aqueous buffer
solution, or by
adjusting the conductivity of the aqueous buffer solution. In some
embodiments, the UF/DF
process is carried out with a permeate flux of at least 1 L=m-2-hr-I, or at
least 5 L=rn-2=hr-1, or
from 5 L=m-2=hr-1 to 25 L=m-2=hr-1, or from 5 L=m-2=hr-1 to 20 L=m-2=hr-1, or
from 5 L-m-2-hr-1
to 15 L-m-2-hr-1, or from 10 L=m-2-hr-1 to 25 L-m-2-hr-1, or from 8 L-m-2-hr-1
to 16 L-m-2-hr-1.
Methods of the present disclosure can also be carried out such that the UF/DF
process
is capable to achieving high diavolume levels, see FIG. 2. Increasing the
number of
diavolumes passed through the membrane during the UF/DF process, while still
maintaining
acceptable levels of permeate flux, enables methods of the present disclosure
to maximize
efficiency and productivity of the overall process. In some embodiments, the
UF/DF process
is carried out with a diavolume of at least 3, or at least 4, or at least 5,
or from 3 to 10, or
from 5 to 10, or from 5 to 8.
The methods of the present disclosure significantly increases the
concentration of the
oligonucleotide in the post-UF/DF retentate that enables the direct
lyophilization of the post-
UF/DF retentate without performing an additional water removal (i.e.,
concentration) step. In
some embodiments, the concentration of the oligonucleotide in the retentate is
at least 20 g/L,
at least 30 g/L, at least 40 g/L, at least 50 g/L, or ranges from 30 g/L to
150 g/L, or ranges
from 50 g/L to 150 g/L, or ranges from 60 g/L to 125 g/L, or ranges from 70
g/L to 125 g/L,
or ranges from 70 g/L to 100 g/L, or from 80 g/L to 90 g/L
The methods of the present disclosure can utilize any suitable UF/DF filter
membrane
known in the art. For example, in some embodiments, the UF/DF process is
carried out using
a membrane having a molecular weight cutoff (MWCO) from 1 kDa to 10 kDa, or
from 1
kDa to 7 kDa, or from 1 kDa to 5 kDa, or from 2 kDa to 4 kDa. In some
embodiments, the
membrane has a MWCO of 3 kDa.
In some embodiments, the UF/DF step is carried out using tangential flow
filtration.
13
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
Methods of the present disclosure may be applied to any oligonucleotide (such
as an
antisense oligonucleotide) having 10 to 50 nucleotides, 10 to 30 nucleotides,
10 to 25
nucleotides, 10 to 20 nucleotides, 16 to 30 nucleotides, 16 to 25 nucleotides
or 16 to 20
nucleotides. In some embodiments, the oligonucleotide is nusinersen. In some
embodiments,
the lyophilized oligonucleotide composition is Spinraza".
In some embodiments, methods of the present disclosure are not to limited to
certain
process steps, or are limited to exclude certain process steps. For example,
in some
embodiments, the method comprises performing at least one ultrafiltration /
diafiltration
(UF/DF) to obtain a retentate, and then performing at least one lyophilization
of the retentate
to obtain a lyophilized composition comprising the oligonucleotide. In other
embodiments,
the method consists of performing a single ultrafiltration / diafiltration
(UF/DF) to obtain the
retentate, and then performing at least one lyophilization of the retentate to
obtain the
lyophilized composition comprising the oligonucleotide In still other
embodiments, the
method consists of performing a single ultrafiltration / diafiltration (UF/DF)
to obtain the
retentate, and then performing a single lyphilization of the retentate to
obtain the lyophilized
composition comprising the oligonucleotide.
In some embodiments, the methods of the present disclosure may be performed
such
that the retentate is not subjected to (i) an additional filtration, (ii) an
additional buffer
exchange, (iii) an additional concentration, and/or (iv) an additional
purification, prior to
performing the lyophilizing of the retentate to obtain the lyophilized
composition. In other
embodiments, methods of the present disclosure may be performed such that the
retentate is
not subjected to any of (i) an additional filtration, (ii) an additional
buffer exchange, (iii) an
additional concentration, and (iv) an additional purification, prior to
performing the
lyophilizing of the retentate to obtain the lyophilized composition. In some
embodiments, the
retentate produced from the UF/DF step is directly lyophilized without any
additional steps.
Another aspect of the present disclosure relates to compositions obtained
using the
methods described herein. In some embodiments, the compositions
comprise an
oligonucleotide, such as Spinraza" (nusinersen). Compositions of the present
disclosure may
be in the form of aqueous solutions, such as a post-UF/DF retentate comprising
an
oligonucleotide, or may be in the form of a solid or semi-solid material, such
as a lyophilized
composition comprising an oligonucleotide.
EXEMPLIFICATION
Materials and Methods
14
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
UF/DF experiments were carried out using a KrosFlo KR2i TFF System (Spectrum
Labs), and a Pellicon 3 (0.11 m2, 31(Da) regenerated cellulose membrane
cassette.
Laboratory-scale lyophilizations were carried out using a LyoStar 2, and
manufacturing-scale
lyophilizations were carried out using a LyoStar 3.
EXAMPLE 1. UF/DF in water
FIG. 9 summarizes the experimental results for a study carried out to
determine how
the permeate flux of a typical UF/DF process, using pure water instead of an
aqueous buffer
solution of the present disclosure, is affected over time as the concentration
of the
oligonucleotide in the retentate increases. In this study, an aqueous solution
containing 10 g/L
of Spinraza' (nusinersen)¨labelled as "Alpha Syn" in FIG 9¨is subjected to a
UF/DF
process using pure water, and both the permeate flux through the membrane and
the
concentration of the oligonucleotide in retentate are measured over time.
Concentration of the
oligonucleotide was measured by spectroscopy measurements taken pre- and post-
operation.
Because the total mass of the ASO in the system was known, the concentrations
were
estimated based on the change in retained volume.
After buffer exchange of the Alpha-Syn ASO into water, an experiment was
carried
out to determine the maximum ASO concentration that could be achieved by
concentrating
the retentate using a buffer solution containing only water. The UF/DF
concentration was
carried out using a transmembrane pressure (TMP) of 20 psi and a crossflow of
1.5 LMM
(liters/minute/meter2). The concentration step began with a retentate
concentration of 10 g/L
and a permeate flux of 7 LMT-T, and as the retentate concentration increased
during the
process (and the retentate volume decreased), the permeate flux dropped
rapidly (FIG. 9).
The permeate flux was reduced to 1 LMF-I at an ASO concentration in the
retentate of
approximately 32 g/L. This experiment demonstrated that concentration of an
ASO to high
concentrations (> 50 g/L) using a UF/DF buffer containing only water is not
feasible.
The study in FIG. 9 indicates that UF/DF processing of oligonucleotides in
water is
limited by membrane surface gelling or concentration polarization phenomena,
which leads
to a significant reduction in membrane permeate flux and creates a maximum
achievable
retentate concentration between 30-40 g/L. Because a concentration of 30-40
g/L is not high
enough to achieve a desirable cake structure during lyophilization, a post-
UF/DF
oligonucleotide in water is typically subjected to an additional unit
operation for the purpose
of volume reduction.
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
EXAMPLE 2. Effects of salt concentration in the aqueous buffer solution on the
permeate flux
The results in Example 1 demonstrated that buffer exchange into water at ideal
API
concentrations is not feasible, due to membrane surface gelling or
concentration polarization
phenomena leading to reduced membrane permeate flux_ However, it was
discovered that
introducing salt additives into the aqueous buffer solution could increase
permeate flux
during the buffer exchange. Experiments attempting to buffer exchange into
water showed
that high conductivity correlated with high permeate flux, and that adding
salt content to the
diafiltration buffer was an effective way to increase permeate flux.
Ammonium acetate was chosen as an experimental additive to increase
conductivity
and therefore permeate flux. Both ammonium and acetate species are compatible
with a
lyophilized API platform process and, therefore, do not introduce any new
substances to the
overall manufacturing process, and both species are known to be volatile in
their neutral
states. Additionally, the pH of ammonium acetate is in a desirable range (6.9-
7.7) based on
the desired pH of an API product.
A three-experiment study was carried out to map the relationship between
ammonium
acetate concentration and permeate flux. The starting material for all three
experiments
included 105 g/L ASO, 710 mM NaCl, and 25 mM Tris, at a pH of 7.2, and all
three
experiments used a transmembrane pressure (TMP) of 35 psi, a crossflow of 3
LMM
(liters/minute/meter2), and membrane loading of 120 g/m2.
In this study, three ammonium acetate aqueous buffer solutions were prepared
in
which the concentration of ammonium acetate was set to 50 mM, 100 mM and 200
mM, and
the resulting permeate fluxes were measured for buffer exchanges carried out
on an aqueous
solution of Spinraza (nusinersen). The results (FIG. 2) show steady-state
permeate flux for
each condition after approximately 3 diayolumes, and a correlation between the
ammonium
acetate concentration and steady-state permeate flux.
As shown in FIG 2, it was observed that the drop in permeate flux that occurs
throughout the UF/DF process is directly proportional to the concentration of
the ammonium
acetate in the aqueous buffer solution. Using an ammonium acetate
concentration of 200 mM
enables the UF/DF process to maintain a permeate flux of greater than 10 L=m-
2=hr-1 even
after 5 diayolumes of the buffer have passed through the membrane. The study
in FIG. 2
shows that controlling the concentration of the salts in the aqueous buffer
solution can enable
UF/DF methods of the present disclosure to achieve high enough concentrations
of
16
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
oligonucleotide in the post-UF/DF retentate that direct lyophilization of the
retentate is
feasible.
FIG. 3. summarizes the experimental results for a related study carried out to
determine how the conductivity of the aqueous buffer solution affects the
permeate flux of
the UF/DF process. The relationship between buffer conductivity and permeate
flux was
explored to determine the minimum salt content needed for UF/DF process. In
this study,
three aqueous buffer solution were prepared in which the conductivity was set
to about 5.1
mS/cm, about 9.8 mS/cm and about 18.9 mS/cm, and the resulting permeate fluxes
were
measured for buffer exchanges carried out on an aqueous solution of Spinraza
(nusinersen).
Conductivity was measured using an Orion VersaStar Pro, Advanced
Electrochemistry Meter.
As shown in FIG. 3, the permeate flux was found to be directly proportional to
the
conductivity of the aqueous buffer solution, such that the increase in
permeate flux is linearly
related to the increase in buffer conductivity The results of this study
demonstrate that
ammonium acetate is an effective facilitator of permeate flux in a suitable
ASO concentration
range. A comparison of the steady-state fluxes (FIG.2) and the buffer
conductivity (FIG. 3)
in this study indicated a linear relationship and, therefore, an ability to
target a specific flux
(Figure 3), which is critical to controlling the UF/DF operation.
Example 3. Correlation between the total concentration of salts in the aqueous
buffer
and maximum oligonucleotide concentration in retentate
FIG. 4 summarizes the experimental results for a study carried out to
determine how
the total concentration of salts in the aqueous buffer solution affects the
final concentration of
the oligonucleotide in the post-UF/DF retentate. In this study, a number of
aqueous buffer
solutions (200 mM ammonium acetate; 50 mM ammonium acetate and 50 mM sodium
acetate; 75 mM ammonium acetate and 25 mM sodium acetate; 90 mM ammonium
acetate
and 10 mM sodium acetate; 7.5 mM ammonium acetate and 42.5 mM sodium acetate;
4 mM
ammonium acetate and 36 mM sodium acetate) were prepared in which the total
concentration of acetate salts was increased from about 4 mM to about 200 mM,
and the
resulting post-UF/DF retentate concentrations were measured for buffer
exchanges carried
out to 8 diavolumes on an aqueous solution of Spinraza (nusinersen).
Following the UF/DF
to 8 diavolumes, a final concentration step was performed to reduce retentate
volume until
permeate flux dropped to <2 LMH.
As shown in FIG 4, it was observed that the concentration of the
oligonucleotide in
the post-UF/DF retentate is directly proportional to the total concentration
of acetate salts in
the aqueous buffer solution. While increasing UF/DF buffer conductivity (total
salt
17
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
concentration) facilitated higher permeate flux, it also facilitated higher
maximum achievable
retentate concentration. This relationship was also linear, demonstrating the
ability to target a
maximum achievable retentate concentration by manipulation of UF/DF buffer
salt
concentration,
The study in FIG 4 surprisingly shows that controlling the concentration of
salts in
the aqueous buffer solution can also control the concentration of the
oligonucleotide in the
retentate
__________________________________________________________________________
enabling the UF/DF process to be carried out in a manner that significantly
increases the retentate concentration, thereby allowing direct lyophilization
of the retentate
(without additional steps) to form solid APIs.
The studies shown in FIGs. 2 and 4 show that the maximum achievable ASO
concentration in the retentate is directly proportional to both the total
acetate concentration in
the UF/DF buffer and the permeate flux. A minimum concentration of 80 g/L was
targeted to
ensure acceptable quality and density of the solid cake, as well as to fit
into an existing
lyophilizer (LyoStar3).
Total salt concentration of the buffer controls permeate flux and maximum ASO
concentration in the retentate that can be achieved, whereby an increase in
total salt results in
a reproducible increase in flux and maximum retentate concentration. By this
method of
control, one can target and reproducibly achieve a desired permeate flux and
maximum
retentate concentration.
Example 4.
Methods of controlling sodium content in the post-lyophilized
oligonucleotide composition
FIG. 5 and Table 1 summarize the experimental results for a study carried out
to
determine how the molar ratio of sodium and ammonium acetate salts in the
aqueous buffer
solution affects the amounts of sodium and ammonium in the post-lyophilized
compositions.
UF/DF experiments in this study all used the following conditions:
= TMP of 35 psi
= Crossflow of 3 LMM
= Membrane loading between 50-275 g/m2.
Lyophilization of the UF/DF pools was carried out in LyoGuard trays, using the
following conditions:
= Initial freezing temperature of -50 C
= Primary drying at 23 C and 100 mTorr
= Secondary drying at 30 C and 100 mTorr.
18
CA 03168716 2022- 8- 19
WO 2021/168306 PCT/US2021/018856
In this study, a series of aqueous buffer solutions (see Table 1) were
prepared in
which the contents of sodium acetate (Na0Ac) and ammonium acetate (NH40Ac)
were
varied such that the molar ratio of sodium to ammonium increased from 0% to
100%, and
mass percentages of sodium and ammonium in the post-lyophilized compositions
were
measured.
Samples of the post-lyophilized solid APIs were analyzed for sodium (using
inductively-coupled plasma optical emission spectrum (ICP-OES)), ammonia
(using the NH3
Bio Test Kit for the Cedex BioHT Analyzer) and acetate content (using the LC-
UV method
(comparison to a standard)) (FIG. 5). The target mass % for sodium was 5.2
0.9%, and the
target for acetate was < 0.8 mass %. No specification on ammonia existed, but
it was desired
to reduce the amount of residual ammonia as much as possible, or to completely
eliminate it
from the API. An intermediate ammonia target of 0.5% was chosen, as it
appeared to be the
lowest consistently achievable level under the tested conditions.
Table 1
Buffer Post-Lyo Post-Lyo
Buffer Post-Lyo
(Na0Ac / Buffer
NH4
Acetate
Ex. Total Acetate Na content
N1140Ac) % Na0Ac content
content
Content (mM) (% mass)
Ratio (% mass) (% mass)
1 200mM NH40Ac 0 0.1
NT
10mM Na0Ac,
2 10 100 0.6 4.1 2.3
90mM NH40Ac
25mM Na0Ac,
3 25 100 1.5 3.5 2.5
75mM NH40Ac
50mM Na0Ac,
4 50 100 3.1 2.2 2.2
50mM NH40Ac
42.5mM Na0Ac,
5 85 50 4.8 0.5 0.8
7.5mM NI-140Ac
34mM Na0Ac,
6 85 40 4.9 0.4 0.5
6mM NH40Ac
36mM Na0Ac,
7 90 40 5.5 0.25 0.742
4mM NH40Ac
38mM Na0Ac,
8 95 40 5.9 0.14 0.597
2mM NH40Ac
9 40mM Na0Ac 100 40 6.3 NT
NT
19
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
The tradeoff between sodium and ammonia was consistent throughout the range of
sodium to ammonium ratios in the buffer systems tested (FIG. 5), demonstrating
the ability to
target specific concentrations of sodium and ammonium in the final product
(solid API). In
all of the examples in FIG. 5, the UF/DF retentates were concentrated to
similar
concentrations of 80-85 g/L. Because the sodium present in solution in the
UF/DF pool was
not removed by lyophilization, the final API sodium values include the sodium
present in the
buffer carried into the lyophilization process. If the UF/DF pool were at a
lower
concentration of ASO (larger volume), the sodium values would be shifted
higher and,
conversely, if the UF/DF pool could be increased to a higher concentration
(smaller volume),
the sodium values would be shifted lower. Any change in final UF/DF retentate
ASO
concentration must be considered when targeting a specific sodium and ammonia
content.
As shown in FIG. 5, it was found that the ratio of ammonium to sodium in the
UF/DF
buffer determines the final content of sodium and ammonium in the post-
lyophilized
composition. Lyophilization of the UF/DF pools was carried out in LyoGuard
trays, using
primary drying conditions of 23 C and 100 mTorr, and secondary drying
conditions of 30 C
and 100 mTorr. Under the lyophilization conditions of this study, the final
content of sodium
and ammonium were observed to be linearly related to the respective molar
ratios of the
sodium acetate and the ammonium acetate.
As illustrated in the related study summarized in FIG. 6, fine-tuning of the
UF/DF
buffer component ratios (e.g., the ratio of ammonium to sodium) can control
the post-
lyophilization sodium content, allowing the solid API to meet certain
specifications such as
the critical sodium content of 5.2%+0.9%. The sodium content results from this
study were
lower than the target of 5.2+0.9 mass%, but the linear trend allows for
prediction of the
necessary UF/DF buffer compositions (of sodium acetate and ammonium acetate)
that would
result in sodium contents within the target range. As shown in FIG. 6,
extrapolating the data
to the center of the target sodium content range predicted that operating the
UF/DF with a
buffer consisting of 85% sodium acetate and 15% ammonium acetate would result
in a
product sodium content of approximately 5.2 mass %.
Example 5. Correlation of acetate content in the post-lyophilized
oligonucleotide
composition with the total acetate content in the aqueous buffer
FIG. 10 summarizes the experimental results for a study carried out to
determine how
the total acetate content in the aqueous buffer solution affects the amount of
acetate in the
post-lyophilized solid API. In this study, a series of aqueous buffer
solutions were prepared
in which the total acetate concentrations were varied from 40 mM to 100 mM
(see Ex. 2-8 in
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
Table 1), and the mass percentage of acetate in the post-lyophilized
compositions were
measured. As shown in FIG. 10, the residual acetate content in the post-lyo
API was found to
be proportional to the total content of acetate salts in the UF/DF buffer. A
linear trend was
observed between the total acetate content in the UF/DF buffer matrix and the
residual
acetate content in the solid API. The buffer conditions that met the acetate
specification of <
0.8 mass % all contained 40 mM total acetate.
The residual acetate content was also not found to be influenced by the
ammonium/sodium cation ratio. Furthermore, based on the volatility of ammonium
acetate
under lyophilization conditions, reduction of the total acetate salt
concentration in the
aqueous buffer solution allowed for removal of acetate to trace levels post-
lyophilization.
Based in part on the experimental studies described above, it was discovered
that
optimization of the ratio of sodium acetate to ammonium acetate in the UF/DF
buffer, along
with reduction of the total acetate salt concentration, can successfully link
an aqueous
downstream process including UF/DF to a lyophilized API.
Example 6. Large scale preparation of lyophilized API
Large-scale experiments were carried out using a fixed molar ratio of the
sodium salt
in the aqueous buffer solution, and the concentration of the oligonucleotide
in the post-
UF/DF retentate (labelled as "Pre-Lyo Oligo. Cone in Table 2 below) and the
moisture
content, sodium content and acetate content of the post-lyophilization
composition were
measured. In these experiments, the oligonucleotide Spinraza (nusinersen) was
subjected to
UF/DF methods of the present disclosure at the fixed molar ratio of the sodium
salt
Based on the previous experimentation, 6 mM ammonium acetate, 34 mM sodium
acetate (85% sodium acetate to 15% ammonium acetate, with a total acetate
concentration of
40 mM) was chosen as the buffer matrix that would best target the endpoints
for maximum
ASO concentration in the retentate, sodium content, and acetate content. The
conditions were
confirmed at lab scale, then repeated at manufacturing (MFG) scale (18 mmol).
The UF/DF
pool from the manufacturing process was split, with a portion lyophilized at
lab scale
(labelled as "Lab Scale Lyo" in Table 2), and the remaining portion
lyophilized at the
manufacturing scale.
As illustrated in Table 2, no significant differences were observed for sodium
and
acetate post-lyophilization, demonstrating that cation control by manipulation
of the UF/DF
buffer is scalable. The maximum achievable UF/DF pool concentrations were the
same at
both scales. The water content in the solid API was observed to be slightly
higher at
manufacturing scale, which was a result of equipment differences. Overall,
scale up of the
21
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
cation and acetate control by manipulation of UF/DF buffer, and facilitation
of permeate flux
and retentate concentration by salt composition were successful, demonstrating
the scalability
of the process.
Table 2: Final UF/DF buffer conditions and results, at lab and manufacturing
scales
Pre-Lyo
ASO Conc. Post-Lyo Post-Lyo Post-Lyo
.
Ex. UF/DF matrix Moisture Sodium
Acetate
in Retentate
(%) (%)
(%)
(g/L)
6/34 (NH40Ac/Na0Ac)
85 1.0 4.9 0.4
Lab Scale UF/DF and Lyo
Eng run 6/34
(NH40Ac/Na0Ac)
11 85 1.1 4.9 0.5
MFG scale UF/DF,
Lab Scale Lyo
Eng run 6/34
12 (NH40Ac/Na0Ac) 85 2.8 4.9
0.5
MFG scale UF/DF and Lyo
5
Bulk lyophilization was performed on materials obtained from manufacturing
scale
run (Ex. 12 in Table 2) using 4 LyoGuard trays for a total liquid volume of
6L. FIG. 7 shows
the 4 LyoGuard trays containing the lyophilized material. The lyophilization
process was
modified to promote maximum removal of volatile UF/DF buffer components. This
bulk
10 lyophilization process involved -50 C freezing, 23 C primary drying
followed by 30 C
secondary drying at 150 mTorr pressure. Moisture content and volatile buffer
components
were successfully removed to trace amounts, meeting the API specifications.
FIG. 8 shows
the lyophilzed material in a LyoGuard tray and subsequently transferred to a
storage bag.
The final buffer chosen was 34 mM Na0Ac and 6mM NH40Ac, and the conditions
and results for the engineering run (Ex. 12 in Table 2) are summarized below:
= Solid API Na Content: 4.9-5.0% (Target 5.2% 0.9%)
= Post-UF/DF Concentration: Allowed for 85 g/L liquid API
= Permeate Flux: Maintained > 10 LMH Flux
= Duration of UF/DF Process: Unit operation complete in 1 day
= Final Acetate Content: Lowest residual acetate post-lyo
= Stability of Post-Lyo Composition: Solid API Stable at 25 C for 31 days
22
CA 03168716 2022- 8- 19
WO 2021/168306
PCT/US2021/018856
While various embodiments of the present disclosure have been shown and
described
herein, it will be obvious that such embodiments are provided by way of
example only.
Numerous variations, changes and substitutions may be made without departing
from the
disclosure herein. Accordingly, it is intended that the disclosure be limited
only by the spirit
and scope of the appended claims.
23
CA 03168716 2022- 8- 19
